No, Viagra (sildenafil) and Cialis (tadalafil) should not be taken together
Taking sildenafil and tadalafil simultaneously is not recommended and lacks evidence for safety or improved efficacy. There is no guideline support for combining these medications, and doing so increases the risk of adverse effects without proven benefit.
Why Combination Use is Not Advised
Lack of Evidence and Guidelines
- No major guideline recommends combining PDE5 inhibitors 1, 2, 3. The AUA Erectile Dysfunction Guideline explicitly states that PDE5 inhibitors should be offered as first-line therapy but makes no mention of combining different agents 1.
- The 2025 European Association of Urology guidelines discuss switching between PDE5 inhibitors but note that "switching between PDE5Is shows limited evidence" and do not endorse combination therapy 3.
Safety Concerns
Combining PDE5 inhibitors amplifies the risk of hypotension and other adverse effects without established safety data:
Hypotension risk: Both drugs work through the same mechanism (PDE5 inhibition), and combining them potentiates vasodilation. The 2025 AHA/ACC Hypertension Guideline warns that PDE5 inhibitors can cause hypotension, especially when combined with CYP3A4 inhibitors, alcohol, or antihypertensives 4.
Drug interactions: The Cialis FDA label emphasizes caution with alpha-blockers and antihypertensives due to blood pressure lowering effects 5. Adding another PDE5 inhibitor compounds this risk.
Documented liver injury: A 2023 case report described severe cholestatic liver injury in a patient who took vardenafil and tadalafil on consecutive days, despite tolerating each medication individually for years (RUCAM score 7 = probable causation) 6. This demonstrates that combining PDE5 inhibitors can produce toxicity not seen with monotherapy.
Adverse Event Profile
Common side effects (headache, flushing, dyspepsia, nasal congestion, myalgia, visual disturbances) follow a dose-response pattern 1. Combining two PDE5 inhibitors effectively increases the total PDE5 inhibition, likely increasing adverse event frequency and severity.
What to Do Instead
Optimize Single-Agent Therapy First
Before considering any alternative approach, ensure the current PDE5 inhibitor trial is adequate 2:
- Verify proper use: Timing (sildenafil 1 hour before, tadalafil 30 minutes to 12 hours before), adequate sexual stimulation, avoiding large meals with sildenafil
- Titrate to maximum dose: Sildenafil up to 100 mg, tadalafil up to 20 mg as needed, or tadalafil 5 mg daily 1
- Address modifiable factors: Hormonal abnormalities (check testosterone), drug interactions, alcohol use, relationship issues 2
Consider Switching, Not Combining
If one PDE5 inhibitor fails after adequate trial:
- Switch to a different PDE5 inhibitor rather than combining 3. While evidence is limited, this is safer than combination therapy.
- Consider tadalafil if on sildenafil: Recent data suggests tadalafil may have advantages, particularly the daily dosing option which maintains steady drug levels and eliminates timing concerns 7, 8.
Alternative Combination Strategies
If monotherapy fails after optimization:
- Add testosterone replacement in hypogonadal men (morning total testosterone <300 ng/dL) 2
- Consider combination with non-PDE5 therapies: Vacuum erection devices, intracavernosal injections, or intraurethral alprostadil 1, 3
Critical Contraindications to Remember
Absolute contraindication: PDE5 inhibitors with nitrates due to severe hypotension risk 4, 9, 5
- Wait ≥24 hours after sildenafil/vardenafil before nitrate use
- Wait ≥48 hours after tadalafil before nitrate use 9, 2
Use with caution: Alpha-blockers, CYP3A4 inhibitors (ketoconazole, ritonavir), antihypertensives, substantial alcohol (≥5 units) 4, 5, 10
The One Exception in Literature
A single 2015 study examined tadalafil 5 mg daily combined with sildenafil 50 mg as needed in 90 patients with severe ED 11. While it showed some improvement in IIEF-5 scores, this was a small study with short follow-up and has not been replicated or incorporated into any clinical guidelines. This isolated finding does not justify routine combination use given the safety concerns and lack of guideline support.